Business Wire

Hao Le Ku (Beijing) Infant and Maternity Co., Ltd. Announces the Launch in Hong Kong of Halykoo ® Line Developed by the Swiss Company APR Applied Pharma Research


Halykoo® baby healthcare consumer products are now available in Hong Kong, promoted and commercialized by the Chinese company Hao Le Ku (HLK), as a result of an exclusive partnership with APR Applied Pharma Research s.a. (“APR”), the Swiss, independent developer of science driven, patent protected healthcare products.

Hong Kong baby and child-specific products market is expected to grow at a CAGR of 2% in the next years, mainly driven by the local demand and a high per capita income. Hong Kong market is very dynamic with sophisticated consumers, historically used to international brands, being very sensitive to innovative and value added products as well as looking for brands which can offer them new meaningful experiences.

Halykoo® brand, the babies’ healthcare expert, matches the request coming from such a demanding market, as its science-driven solutions are the perfect combination of Swiss, high-quality pharmaceutical expertise with an extensive understanding of child and caregivers needs.

Halykoo® offers to parents a new way for the daily healthcare of their children, by turning a potentially stressful moment into a pleasant and rewarding experience, thanks to smart and innovative product deliveries intended to simplify their use for parents and reduce the hassle for babies.

In the first phase of launching, the distribution will focus mainly on baby and health stores that offer specialized health products and health counselling. In addition, HLK will start to build up their own online store, targeting young and highly-educated parents who are digital lovers with high purchasing power. Universal Health International Group Holding Limited has been appointed by HLK as the only distributor in Hong Kong and Macao district.

Supporting Halykoo® line at best for brand building and grapping a significant share of market, HLK has carried out a comprehensive media and communication campaign, with a specific focus on online marketing as well as social networks according to the digital mindset of the potential target. In addition, special promotions will be arranged in different distribution points through trained promoters, to introduce to young mothers Halykoo® products.

“We’re investing a lot on Halykoo® launch as we mean to build up a strong brand awareness and achieve a remarkable market share in the first year,” said Mr. Ricky Ren CEO of HKL. “We really want Halykoo® to be a great success in Hong Kong as this could be the stepping stone towards Great China.”

To celebrate the launch, HLK has participated to the 25th Eugene Baby Expo, one of the biggest international B2C baby-related exhibition, from 4th to 7th August in Wan Chai. The exhibition, held twice a year, had a record of over 500,000 visits and 800 exhibitors in average, thus being the perfect showcase for Halykoo® product range.

“We are very proud to see Halykoo® products on Hong Kong stores shelves – said Mr. Paolo Galfetti, CEO of APR – and we strongly believe that Halykoo® Swiss quality products will be soon appreciated by Hong Kong consumers, in a market where baby and child-specific products saw a steady growth in 2016. ”

About Halykoo®
Halykoo®, the babies’ healthcare expert, is the first global brand offering the most comprehensive range of consumer healthcare products. It matches formulations s specifically focused on each of the main stages of children’s growth, since birth, with smart and innovative deliveries intended to simplify their use for parents and reduce the hassle for babies.

The product range has been carefully developed to solve the main daily babies’ healthcare discomforts in the major therapeutic areas for turnover such as skin care, cough & cold, eye, ear & mouth and food supplementation. As of today, the portfolio includes over 18 already developed products and 10 additional products are under development to be finalized in 2018.

Conceived and formulated applying the value of Swiss pharmaceutical expertise, Halykoo provides science-driven pediatric solutions that perfectly combine smart deliveries, thanks to the application of the pharmaceutical technology knowledge, with advanced formulations, balanced on the physiological babies’ needs.

For more info about Halykoo®, please visit:

About Hao Le Ku (Beijing) Infant and Maternity Co., Ltd.
Hao Le Ku is a leading company engaged in marketing of baby products. We are a service oriented, high quality and ethically-driven. Our company was founded in 2013 and registered in Tian Jin, China. Our revenue has been increasing significantly during the last 2 years and the growth rate recorded is more than 100%. Our baby protection products covered many different categories in the industry.

About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science-driven, patent protected healthcare products. The Company identifies, develops and licenses science- driven, value-added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. Specifically, APR is currently focused on 2 (two) major areas: (i) internally developed and financed (alone or with our co-development partners) proprietary, value-added products to be licensed to healthcare companies for their commercialization, and (ii) support to third-party projects, by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products commercialized in all major markets, combined with a compelling pipeline of products at different development stages. APR has entered into licensing and partnership agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis.
For more information please visit or

Contact information

APR Applied Pharma Research s.a.,
Paolo Galfetti; CEO
T: +41 91 6957020
email to
Hao Le Ku (Beijing) Infant and Materniity Co., Ltd.
Ricky Ren; CEO
T: +1 (626) 328-9241
email to
Havas PR Milan - Press Office
Sara Bernabovi
T: +39 02 85457032 or email to

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Global Survey Points to Key Issues, Needs and Gaps in Fight to End Smoking19.3.2018 17:00Tiedote

The Foundation for a Smoke-Free World released findings today from a global survey to better understand smokers, their experiences, and challenges they face when they try to quit smoking. The survey also highlights their awareness regarding the harm caused by smoking and how their perceptions of cigarettes, alternative products, and nicotine influence their motivation to move away from smoking. The data will shape the development of research to determine the best solutions to accelerate the end of smoking across diverse cultures and economic conditions. This press release features multimedia. View the full release here: Figure 1: Which of the following situations, if any, apply to you? (% - Top Three Answers per Country) (Graphic: Business Wire) The 2018 State of Smoking Survey included 17,421 current smokers, ex-smokers, and non-smokers from 13 countries: Brazil, France, Greece, India, Israel, Japan, Lebanon, Malawi, New Zealan

New Documentary Raises Global Water Crisis Awareness As 844 Million People Still Lack Access to Clean Drinking Water19.3.2018 16:12Tiedote

Procter & Gamble’s (P&G) non-profit Children’s Safe Drinking Water (CSDW) Program and National Geographic are raising awareness about the global water crisis with the release of a new documentary and national survey in conjunction with World Water Day. The documentary, titled “The Power of Clean Water,” follows the lives of three women and their families, providing a first-hand perspective on the daily challenges of accessing clean drinking water. As the film progresses, viewers witness how P&G’s Purifier of Water packets, distributed by partners ChildFund in Indonesia, CARE International in Kenya and World Vision in Mexico, have helped transform these communities. This press release features multimedia. View the full release here: P&G conducted a survey* to understand Americans' level of awareness and concern with the global water crisis and its effects. (Graphic: Business Wire) Global awareness of the water crisis is growing,

If You Previously Purchased or Otherwise Acquired Certain Petrobras Securities, You Could Get a Cash Payment from a Class Action Settlement19.3.2018 16:00Tiedote

The following statement is being issued by Pomerantz LLP regarding In re Petrobras Securities Litigation. Important Legal Notice from the United States District Court for the Southern District of New York Two proposed settlements have been reached in a securities class action lawsuit brought by investors against Petróleo Brasileiro S.A. (“Petrobras”) and certain of its affiliates, underwriters, external auditors, and current and former directors and officers. The Settlements include certain securities issued by Petrobras. Petrobras, the Underwriter Defendants, and PricewaterhouseCoopers Auditores Independentes (“PwC Brazil”) deny any and all allegations of wrongdoing, and the District Court has not decided who is right. If you requested exclusion in response to the previously mailed notice of pendency of class action dated May 9, 2016, you are included in this Settlement, and you must request exclusion again if you do not want to be included in the Settlement Class. Am I included in th

YuppTV Awarded Rights for Vivo-IPL 2018 for Australia, Continental Europe and South East Asia19.3.2018 15:30Tiedote

As the most awaited event of the year, the Vivo-IPL 2018, which is Season 11 of the world’s biggest T20 tournament, approaches, cricket fans have yet another reason to rejoice! YuppTV, the world’s leading OTT brand for South-Asian content, has announced that it has awarded the exclusive digital & television media rights for Vivo-IPL 2018 by Star India for Europe, South America, South East Asian countries, and non-exclusive rights for Australia. Scheduled to take place from 7 April to 27 May 2018, the Vivo-IPL 2018, the biggest and most eagerly awaited cricketing extravaganza in a decade of IPL history, will witness eight teams playing this season including Chennai Super Kings and Rajasthan Royals that are back in action after serving two years of suspension. With the enormous anticipation and such high stakes in the offing and an exciting line-up of teams, cricket fans the world over have the perfect window to catch every swing and ball of the Vivo-IPL 2018, thanks to the YuppTV app. C

Intuit’s Open Platform Strategy Transforms How QuickBooks Online Accountant Users Serve Their Clients19.3.2018 15:30Tiedote

Delivering on its open platform approach to provide seamless integrations across an ecosystem of accounting-focused solutions, Intuit (Nasdaq:INTU) today announced that QuickBooks Online Accountant (QBOA) now allows accounting professionals to manage all of their clients – even those that don’t use QuickBooks – within the product. This innovation is now available globally for QBOA users in the United States, Canada, United Kingdom, Australia, South Africa and France. It enables accountants to organize and view client information, notes and details in one consolidated place – meaning fewer headaches, missed deadlines and confusion. “With this new capability, QBOA continues to evolve as the one place for our accounting and tax professionals to meet the needs of all their clients, no matter what accounting product or spreadsheet tool they use,” said Rich Preece, leader of the Accountant Segment, Small Business and Self Employed Group at Intuit. “We’re pleased our open platform strategy co

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease19.3.2018 15:08Tiedote

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA’s Fast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need in an effort to get treatments to those in need sooner. This designation is based on Boehringer Ingelheim’s Investigational New Drug application (IND) of nintedanib for the treatment of SSc-ILD and the anticipated efficacy and safety data from SENSCIS™ (Safety and Efficacy of Nintedanib in Systemic SClerosIS), a double-blind, randomized, placebo-controlled global Phase III trial. This pivotal study is fully enrolled, including more than 520 patients from 32 countries. “This Fast Track designation is an encouraging step in our ongoing research and commitment to advancing care of those with systemic sclerosis with interstiti

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme